Direct-to-consumer (DTC) genetic testing lets you order a DNA test online, collect a saliva sample at home, and receive results digitally without going through a doctor. Companies like 23andMe and AncestryDNA are the most recognizable names in this space, but dozens of smaller companies now offer tests covering everything from disease risk to skincare recommendations. The appeal is obvious: accessible, relatively affordable genetic information without a clinical visit. But the technology has real limitations worth understanding before you spit in a tube.
Types of DTC Genetic Tests
DTC tests fall into three broad categories, each with different levels of scientific backing and regulatory oversight.
Ancestry and genealogy tests estimate where your ancestors likely came from, break down your ethnicity, and can connect you with genetic relatives who’ve also tested. These are the most popular consumer tests and are not reviewed by the FDA.
Health and disease risk tests estimate your genetic predisposition to conditions like celiac disease, Parkinson’s disease, and Alzheimer’s disease. Some also include carrier screening, which tells you whether you carry a gene variant for conditions like cystic fibrosis or sickle cell disease that could be passed to your children. A newer addition to this category is pharmacogenomics reporting, which suggests how you might respond to certain medications based on your DNA.
Lifestyle and wellness tests claim to offer DNA-based guidance on nutrition, fitness, weight loss, sleep, and skincare. These sit on the weakest scientific foundation of the three categories and receive no FDA review.
How the Testing Works
You order a kit, register it online, provide a saliva sample, and mail it back in a prepaid package. Results typically arrive digitally within a few weeks. No blood draw, no doctor’s office, no insurance billing.
Most DTC tests don’t sequence your entire genome. Instead, they use a technology called SNP-chip genotyping, which checks for the presence or absence of specific known genetic variants scattered across your DNA. Think of it as scanning a book for particular words rather than reading every page. This approach detects common genetic variants reliably but struggles with rare ones. A study in the journal Genetics in Medicine found that 40% of rare variants flagged in DTC raw data turned out to be false positives when checked with clinical-grade testing.
Some companies now offer whole genome sequencing, which reads nearly your entire genetic code. This provides far more data but costs significantly more and still requires interpretation, which is where things get complicated.
What the Results Actually Tell You
For ancestry, the results are relatively straightforward: percentage breakdowns of geographic origins and lists of DNA-matched relatives. The accuracy of ethnicity estimates varies by company because each one uses a different reference database.
Health results are more nuanced. For conditions caused by single gene variants, like carrier status for cystic fibrosis, the information can be clear-cut. But for common diseases like type 2 diabetes or heart disease, your risk is shaped by hundreds or thousands of genetic variants working together, plus your environment, diet, and lifestyle. Companies calculate what’s called a polygenic score to estimate this combined genetic risk. In 2019, 23andMe launched a polygenic score report for type 2 diabetes that shows consumers how factors like weight and diet interact with their genetic profile to shift their overall risk. Early research suggests these scores can motivate healthier behavior, particularly for cardiovascular disease, but they’re still a rough tool.
The biggest gap is in what these tests miss. 23andMe’s BRCA report, for example, checks for only three variants in the BRCA1 and BRCA2 genes. Those three variants are most relevant for people of Ashkenazi Jewish descent. Because thousands of other disease-causing BRCA variants exist, this approach would miss roughly 80% of people who actually carry a harmful BRCA mutation. A clean result on a DTC test is not the same as a clean result from clinical genetic testing ordered by a specialist.
FDA Oversight Varies by Test Type
Not all DTC tests face the same regulatory scrutiny. The FDA uses a tiered approach based on how much a test could affect medical decisions.
- Ancestry and general wellness tests are not reviewed by the FDA.
- Carrier screening tests are exempt from premarket review but must follow specific regulatory requirements.
- Genetic health risk tests require FDA clearance for a company’s first test. After that, additional tests can often be offered without further review, as long as they meet established requirements and aren’t for higher-risk uses.
- Pharmacogenetic tests require FDA premarket review and clearance.
- Cancer predisposition tests are considered moderate to high risk and require FDA premarket review and clearance.
When the FDA does review a test, it assesses whether the test accurately measures what it claims to measure, whether that measurement actually predicts a health condition, and whether the results are presented clearly enough for a consumer to understand without professional help.
All labs processing these samples in the United States must be certified under the Clinical Laboratory Improvement Amendments (CLIA) program, which regulates laboratory testing performed on humans. This covers the quality of the lab work itself, though it doesn’t address the accuracy of the interpretive reports you receive.
Privacy and Your Genetic Data
When you send your DNA to a testing company, you’re handing over the most personally identifiable information that exists. Each company handles this data differently, and the details matter.
Key questions to check in any company’s privacy policy: Will they share your genetic data with pharmaceutical companies, academic researchers, or other third parties? If so, will the shared data include identifying information like your name or date of birth? Will you be notified when your data is shared or sold? Many companies offer opt-in research programs where your de-identified data contributes to studies, but the degree of de-identification varies.
Even companies that promise not to share your data may be compelled to hand it over in response to a warrant, court order, or other legal requirement. Many companies now disclose their policies on law enforcement access, so it’s worth reading the fine print before you order.
Legal Protections Against Discrimination
The Genetic Information Nondiscrimination Act (GINA) provides important but incomplete protections. Under GINA, group health insurance plans cannot use your genetic information to set premiums, determine eligibility, or make coverage decisions. Plans also cannot require you to take a genetic test or collect genetic information, including family medical history, for underwriting purposes.
GINA also covers employment discrimination. Employers cannot use genetic information in hiring, firing, or promotion decisions.
The significant gap: GINA does not cover life insurance, disability insurance, or long-term care insurance. Companies offering these products can, in most states, ask about and use genetic test results when making coverage decisions. This is worth considering before testing, particularly if you plan to apply for any of these policies in the future.
When DTC Results Need Clinical Follow-Up
If a DTC test flags you as having an elevated risk for a serious condition, the single most important thing to know is that the result needs confirmation through clinical-grade testing. The 40% false positive rate for rare variants in DTC raw data makes this essential, not optional. A genetic counselor or your doctor can order confirmatory testing that uses more precise methods and examines a broader range of variants than DTC panels cover.
Conversely, a negative result on a DTC test doesn’t guarantee you’re in the clear. Because these tests check for only a small fraction of known disease-causing variants, they can miss mutations that a comprehensive clinical test would catch. If you have a strong family history of a condition like breast cancer or hereditary heart disease, clinical genetic testing through a specialist will give you a far more complete picture than any consumer product currently available.